GlassScriptPhysician profile
Philip J Blount
NPI 1831136175
$102,516.20
in general payments reported to CMS, 2019-2025
16 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $7,959 · 2021: $12K · 2022: $20K · 2023: $24K · 2024: $11K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $4,750 · Travel and Lodging: $4,425 · Food and Beverage: $1,942 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,825.00 |
| Consulting Fee | $4,750.00 |
| Travel and Lodging | $4,424.57 |
| Food and Beverage | $1,941.86 |
| Education | $268.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $65,135.52 | 2022-2025 | Botox |
| Allergan, INC. | $36,208.23 | 2019-2022 | |
| Abbott Laboratories | $337.92 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $286.28 | 2022-2023 | Dysport |
| Merz Pharmaceuticals, LLC | $220.32 | 2023-2025 | Xeomin |
| Pfizer INC. | $84.50 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $46.47 | 2019-2025 | Euflexxa |
| Scilex Pharmaceuticals INC. | $37.93 | 2019 | |
| Avanir Pharmaceuticals, INC. | $30.09 | 2019 | |
| Electronic Waveform Lab, INC. | $25.00 | 2020 | |
| Fidia Pharma USA INC. | $19.24 | 2019 | |
| Revance Therapeutics, INC. | $18.73 | 2024 | Daxxify |
| Metacel Pharmaceuticals LLC | $18.25 | 2023 | Ozobax |
| Microtransponder, INC. | $17.36 | 2024 | |
| Boston Scientific Corporation | $15.77 | 2025 | Wavewriter Alpha Prime 16 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.59 | 2025 | Hyqvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Blount listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.